- UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis (ptosis), or low-lying eyelid
- Clinical studies have shown an average one-millimeter lift of the upper eyelid, with results in as little as five minutes post-dose
- UPNEEQ(R) is available through RVL Pharmaceuticals’ dedicated e-commerce platform, Elevate, which supports subscription ordering by HCPs and RVL Pharmacy patients
- RVL is poised to be an integral player in the global medical aesthetic market, which is estimated to reach $18 billion by 2027
RVL Pharmaceuticals (NASDAQ: RVLP), is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis (ptosis, or low-lying eyelids) in adults. The company believes there is significant potential for UPNEEQ(R) to create value for healthcare providers, patients, and shareholders.
“Looking ahead, we believe that UPNEEQ is a significant potential value driver,” noted Brian Markison, RVL’s CEO (https://ibn.fm/A1buv).
UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis, or low-lying eyelid. UPNEEQ(R) was approved in July 2020 and since its debut, medica professionals have been prescribing it for patients. UPNEEQ(R) has garnered significant media attention as well, having been featured in top-tier media outlets including Vogue, Elle, and Allure. Patients can purchase UPNEEQ(R) from eye care and medical aesthetic professionals or through RVL Pharmacy LLC, the company’s wholly owned pharmacy.
This once-daily eye drop has shown an average one-millimeter upper eyelid lift, improving appearance and the superior visual field in patients with a functional deficit. Clinical studies have also shown that patients’ eyelids lift in as little as five minutes post-dose, with the lift effect lasting as long as eight hours. This level of effectiveness presents a viable, more accessible, non-surgical alternative for patients with droopy eyelids, a unique value proposition only available with UPNEEQ(R).
Going forward, the company plans to drive adoption through Elevate, the company’s new e-commerce platform, which allows the company to offer subscription options and serve Business-to-Business-to-Consumer (“B-B-C”) clients.
“We expect that our future marketing mix will shift to the consumer to complement our personal selling efforts across the board,” noted Markison. “Conversions to Elevate, our new e-commerce platform, which is designated to enable us to offer subscription options to all our customers and a B-B-C program for direct purchasing locations, are off to an encouraging start.”
These significant strides will [help to] enable RVL to become a significant player in the medical aesthetics market, which is expected to reach $18 billion by 2027. The company is believed to be positioning itself to take advantage of this market growth, focused on providing an innovative, non-invasive solution to a common problem.
For more information, visit the company’s website at www.RVLPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to RVLP are available in the company’s newsroom at https://ibn.fm/RVLP